Orlistat Polpharma blocks some of the fat that you eat, keeping it from being absorbed by your body.
Orlistat Polpharma is used together with a reduced-calorie diet and weight maintenance to treat obesity in people with certain risk factors (such as diabetes, high blood pressure, and high cholesterol or triglycerides).
Orlistat Polpharma may also be used for purposes not listed in this medication guide.
It is dangerous to purchase Orlistat Polpharma on the Internet or from vendors outside of the United States. Medications distributed from Internet sales may contain dangerous ingredients, or may not be distributed by a licensed pharmacy. Samples of "alli" purchased on the Internet have been found to contain sibutramine (Meridia), a prescription weight loss medication that can have dangerous side effects in certain people. For more information, contact the U.S. Food and Drug Administration (FDA) or visit www.fda.gov/buyonlineguide.
Orlistat Polpharma indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Orlistat Polpharma is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Orlistat Polpharma is also indicated to reduce the risk for weight regain after prior weight loss. Orlistat Polpharma is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia).
Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5'5" would have a BMI of 30.
Table 1 Body Mass Index (BMI), kg/m2*
*
Conversion Factors:
Weight in lbs ÷ 2.2 = weight in kilograms (kg)
Height in inches × 0.0254 = height in meters (m)
1 foot = 12 inches
How should I use Orlistat Polpharma?
Use Orlistat Polpharma as directed by your doctor. Check the label on the medicine for exact dosing instructions.
An extra patient leaflet is available with Orlistat Polpharma. Talk to your pharmacist if you have questions about this information.
Take Orlistat Polpharma by mouth with or up to 1 hour after each main meal that contains fat (up to 3 per day).
If a meal is missed or contains no fat, do not take a dose of Orlistat Polpharma.
You should take a multivitamin supplement containing vitamins A, D, E, and K to ensure good nutrition. The supplement should be taken at least 2 hours before or after you take Orlistat Polpharma, such as at bedtime.
If you also take a thyroid hormone (eg, levothyroxine), do not take it within 4 hours before or after taking Orlistat Polpharma. Check with your doctor if you have questions.
If you also take cyclosporine, do not take it within 3 hours before or after taking Orlistat Polpharma. Check with your doctor if you have questions.
If you miss a dose of Orlistat Polpharma, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Orlistat Polpharma.
Uses of Orlistat Polpharma in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
Use: Labeled Indications
Obesity management:
OTC: Weight loss in overweight adults when used along with a reduced-calorie and low-fat diet.
Rx: Obesity management, including weight loss and weight maintenance, when used in conjunction with a reduced-calorie diet; to reduce the risk for weight regain after prior weight loss.
Limitations of use: Orlistat Polpharma is indicated for obese patients with an initial body mass index of ≥30 kg/m in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia).
Orlistat Polpharma description
Orlistat Polpharma is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Orlistat Polpharma works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.
Orlistat Polpharma dosage
Orlistat Polpharma Dosage
Generic name: Orlistat Polpharma 120mg
Dosage form: capsule
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Recommended Dosing
The recommended dose of Orlistat Polpharma is one 120-mg capsule three times a day with each main meal containing fat (during or up to 1 hour after the meal).
The patient should be on a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat. The daily intake of fat, carbohydrate, and protein should be distributed over three main meals. If a meal is occasionally missed or contains no fat, the dose of Orlistat Polpharma can be omitted.
Because Orlistat Polpharma has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene, patients should be counseled to take a multivitamin containing fat-soluble vitamins to ensure adequate nutrition. The vitamin supplement should be taken at least 2 hours before or after the administration of Orlistat Polpharma, such as at bedtime.
For patients receiving both Orlistat Polpharma and cyclosporine therapy, administer cyclosporine 3 hours after Orlistat Polpharma.
For patients receiving both Orlistat Polpharma and levothyroxine therapy, administer levothyroxine and Orlistat Polpharma at least 4 hours apart. Patients treated concomitantly with Orlistat Polpharma and levothyroxine should be monitored for changes in thyroid function.
Doses above 120 mg three times a day have not been shown to provide additional benefit.
Based on fecal fat measurements, the effect of Orlistat Polpharma is seen as soon as 24 to 48 hours after dosing. Upon discontinuation of therapy, fecal fat content usually returns to pretreatment levels within 48 to 72 hours.
More about Orlistat Polpharma (Orlistat Polpharma)
Amiodarone: Orlistat Polpharma may decrease the serum concentration of Amiodarone. Monitor therapy
Anticonvulsants: Orlistat Polpharma may decrease the serum concentration of Anticonvulsants. Exceptions: Fosphenytoin; PENTobarbital; Thiopental. Monitor therapy
Antiretroviral Agents: Orlistat Polpharma may decrease the serum concentration of Antiretroviral Agents. Monitor therapy
CycloSPORINE (Systemic): Orlistat Polpharma may decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer Orlistat Polpharma at least 3 hours before or after oral cyclosporine. Monitor for decreased serum concentrations of oral cyclosporine, even with the recommended dose separation. Consider therapy modification
Levothyroxine: Orlistat Polpharma may decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and Orlistat Polpharma by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism. Consider therapy modification
Multivitamins/Fluoride (with ADE): Orlistat Polpharma may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, Orlistat Polpharma may impair absorption of fat-solube vitamins. Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of Orlistat Polpharma. Consider therapy modification
Multivitamins/Minerals (with ADEK, Folate, Iron): Orlistat Polpharma may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, Orlistat Polpharma may impair the absorption of fat-soluble vitamins. Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of Orlistat Polpharma. Consider therapy modification
Multivitamins/Minerals (with AE, No Iron): Orlistat Polpharma may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, Orlistat Polpharma may impair absorption of fat-solube vitamins. Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of Orlistat Polpharma. Consider therapy modification
Paricalcitol: Orlistat Polpharma may decrease the serum concentration of Paricalcitol. Management: Monitor clinical response to paricalcitol closely when used with Orlistat Polpharma. When this combination must be used, consider administering paricalcitol at least 1 hour before or 4 to 6 hours after the administration of Orlistat Polpharma Consider therapy modification
Propafenone: Orlistat Polpharma may decrease the serum concentration of Propafenone. Monitor therapy
Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Consider therapy modification
Vitamin D Analogs: Orlistat Polpharma may decrease the serum concentration of Vitamin D Analogs. More specifically, Orlistat Polpharma may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with Orlistat Polpharma. If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after Orlistat Polpharma. Exceptions: Calcipotriene; Calcitriol (Topical); Tacalcitol. Consider therapy modification
Vitamin K Antagonists (eg, warfarin): Orlistat Polpharma may enhance the anticoagulant effect of Vitamin K Antagonists. Monitor therapy
Vitamins (Fat Soluble): Orlistat Polpharma may decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of Orlistat Polpharma. Similar precautions do not apply to parenterally administered fat soluble vitamins. Exceptions: Calcipotriene. Consider therapy modification
The majority of unwanted effects related to the use of Orlistat Polpharma result from its local action in your digestive system. These commonly include: urgent or increased need to open the bowels, flatulence (wind) with discharge, oily discharge and oily or fatty stools. The possibility of this happening may increase if Orlistat Polpharma is taken with a diet high in fat. In addition your daily intake of fat should be distributed evenly over three main meals because if Orlistat Polpharma is taken with a meal very high in fat, the possibility of gastrointestinal effects may increase. The more fat you eat, the more fat in your stools, and the more you will experience these dietary events. The frequency and onset of these dietary events varies from one person to another and depends on how much fat is consumed. They usually occur more frequently in the beginning of your program, and will gradually disappear as you develop new eating habits. Most importantly, you can control these dietary events when you control your fat intake. It is not Orlistat Polpharma alone, but the excess fat that you eat while taking Orlistat Polpharma that causes these events. Try not to exceed your daily fat allowance as calculated by your doctor or dietician.
Rare cases of allergic reactions have occurred with Orlistat Polpharma. The main symptoms are itching, rash, wheals (slightly elevated, itchy skin patches that are paler or redder than surrounding skin), difficulty in breathing, nausea, vomiting and feeling unwell. Very rarely increases in liver enzyme levels have been reported. If you are concerned about these or notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.
Do not take Orlistat Polpharma if you are pregnant. Weight loss is not recommended during pregnancy, even if you are overweight or obese.
You should not take this medication if you are allergic to Orlistat Polpharma, if you are pregnant, or if you have gallbladder problems or chronic malabsorption syndrome (an inability to absorb food and nutrients properly).
Before taking Orlistat Polpharma, tell your doctor if you have an underactive thyroid, a history of gallstones or pancreatitis, type 1 or type 2 diabetes, an eating disorder, liver or kidney disease, or if you take other weight-loss medications (prescription or over-the-counter).
Do not give over-the-counter Orlistat Polpharma (alli) to a child younger than 18 years old. Prescription Orlistat Polpharma should not be used by anyone age 12 to 18 without the advice of a doctor.
Orlistat Polpharma should be used only by the person for whom it was prescribed. Never share Orlistat Polpharma with another person, especially someone who has a history of eating disorder. Keep the medication in a place where others cannot get to it.
Orlistat Polpharma is only part of a complete program of treatment that also includes diet, exercise, and weight control. Your daily intake of fat, protein, and carbohydrates should be evenly divided over all of your daily meals. Follow your diet, medication, and exercise routines very closely.
Avoid a diet that is high in fat. High-fat meals taken in combination with Orlistat Polpharma can increase your risk of unpleasant side effects on your stomach or intestines.
DailyMed. "ORLISTAT: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Orlistat Polpharma are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Orlistat Polpharma. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!
